Clinical and Basic Research

The fellow may participate in any of the ongoing research projects but will be encouraged to design and implement a project that could be conducted over the course of his/her fellowship. This should be of the nature to yield at least two publications in peer reviewed journals.

The current ongoing projects fall under one of the following areas:

  1. Heart Failure
  2. Post-transplant: Cardiac Allograft Vasculopathy
  3. Basic
  4. Multi-Center Research Trials
  5. CHF
    1) Heart failure drug trials
    2) CHF and arrhythmia - ICD versus drug therapy.

Basic Research

A strong commitment to basic research needs to be present since these projects take a long time just to learn the investigational techniques.

  1. Endothelial function using Flusol
  2. NC020 in the diet may improve endothelial function in a transplant model
  3. Endothelial cell/smooth muscle cell proliferation in response to lymphocyte stimulated cytokine production
  4. Changes in oxidative metabolism in rejection and CAD
  5. In-vivo gene transfer in a transplanted heart
  6. Myoblast transplantation in a porcine model

Clinical Trials

The following is a list of the current ongoing trials in which the fellow may participate.

  • Amlodipline versus placebo effect on survival of patients with CHF
  • IV administration of TRK-820 to patients with hyponatremia coincident with CHF
  • Prevention of sudden cardiac death in heart failure
  • Acute hemodynamic effects of IV L-753,037 in patients with symptomatic heart failure
  • Mycophenolate mofetil or azathioprine in combination with cyclosporin and corticosteroids for rejections, grafts and patient survival in cardiac allograft recipients
  • Neoral versus Sandimmune for safety, tolerability and vascular effects in cardiac transplant patients
  • Tacrolimus and cyclosporin regimens in cardiac transplant patients
  • Chronic use vesnarinone in heart failure
  • Effects of Bosentan on morbidity of patients with moderate to severe CHF
  • Effect of oral Azimilide Dihydrochloride versus placebo on survival in recent post MI patients at risk of sudden cardiac death
  • WCD pre market approval investigational plan
  • IV milrinone versus placebo in reduction of hospital days in the 60 days following entry into study for treatment of left-sided heart failure (milrinone exacerbations of CHF)
  • Oral levosimendan as substitute for IV inotropic support on end-stage heart failure